-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

Benzinga·08/07/2026 20:25:15
语音播报
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.